Sasha E Larsen, Jesse H Erasmus, Valerie A Reese, Tiffany Pecor, Jacob Archer, Amit Kandahar, Fan-Chi Hsu, Katrina Nicholes, Steven G Reed, Susan L Baldwin, Rhea N Coler
Author Information
Sasha E Larsen: Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA 98109, USA. ORCID
Jesse H Erasmus: HDT BioCorp, Seattle, WA 98102, USA. ORCID
Valerie A Reese: Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA 98109, USA. ORCID
Tiffany Pecor: Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA 98109, USA.
Jacob Archer: HDT BioCorp, Seattle, WA 98102, USA.
Amit Kandahar: HDT BioCorp, Seattle, WA 98102, USA.
Fan-Chi Hsu: Hematologics Inc., Seattle, WA 98121, USA.
Katrina Nicholes: HDT BioCorp, Seattle, WA 98102, USA.
Steven G Reed: HDT BioCorp, Seattle, WA 98102, USA.
Susan L Baldwin: Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA 98109, USA.
Rhea N Coler: Center for Global Infectious Disease Research, Seattle Childrens Research Institute, Seattle, WA 98109, USA.
(M.tb), a bacterial pathogen that causes tuberculosis disease (TB), exerts an extensive burden on global health. The complex nature of M.tb, coupled with different TB disease stages, has made identifying immune correlates of protection challenging and subsequently slowing vaccine candidate progress. In this work, we leveraged two delivery platforms as prophylactic vaccines to assess immunity and subsequent efficacy against low-dose and ultra-low-dose aerosol challenges with M.tb H37Rv in C57BL/6 mice. Our second-generation TB vaccine candidate ID91 was produced as a fusion protein formulated with a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant in a stable emulsion) or as a novel replicating-RNA (repRNA) formulated in a nanostructured lipid carrier. Protein subunit- and RNA-based vaccines preferentially elicit cellular immune responses to different ID91 epitopes. In a single prophylactic immunization screen, both platforms reduced pulmonary bacterial burden compared to the controls. Excitingly, in prime-boost strategies, the groups that received heterologous RNA-prime, protein-boost or combination immunizations demonstrated the greatest reduction in bacterial burden and a unique humoral and cellular immune response profile. These data are the first to report that repRNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing CD4+ and CD8+ T-cell epitopes.
